A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 5-6, 2013, Pages 406-413

  Vincenzi, Fabrizio ^a   Corciulo, Carmen ^a   Targa, Martina ^a   Casetta, Ilaria ^b   Gentile, Mauro ^b   Granieri, Enrico ^b   Borea, Pier Andrea ^a   Popoli, Patrizia ^c   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenosine receptors; ALS patients; Cyclic AMP assays; Human lymphocytes; Saturation binding experiments

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENYLATE CYCLASE; CYCLIC AMP; FORSKOLIN; MESSENGER RNA; RILUZOLE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE RECEPTOR;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE REVISED SCORE; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOCYTE; LYMPHOCYTE MEMBRANE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUTRITIONAL STATUS; ONSET AGE; OUTPATIENT CARE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; RESPIRATORY FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED;

ADENOSINE A2 RECEPTOR AGONISTS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CYCLIC AMP; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84881365511     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.793358     Document Type: Article

References (35)

1. Kiernan MC, Vucic 1. S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011 ; 377: 942-55
2. Eisen A. Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve. 1995 ; 18: 74-52
3. Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai L, et al. Clinical trials for neuroprotection in ALS. CNS & Neurol Disord Drug Targets. 2010 ; 9: 305-13
4. Perry J J, Shin D S, Tainer J A. Amyotrophic lateral sclerosis. Adv Exp Med Biol. 2010 ; 685: 9-20
5. Hardiman O, van den Berg LH, Kiernan MC. C linical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 ; 7: 639-49
6. Rothstein JD. Current hypothesis for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009 ; 65: S3-9
7. Volontè C, Amadio S, Cavaliere F, D 'A mbrosi N, Vacca F, Bernardi G. Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neural Disord. 2003 ; 2: 403-12
8. Burnstock G. P urinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008 ; 7: 575-90
9. Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, et al. A 2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J. 2010 ; 24: 587-98
10. Volontè C, Apolloni S, Carrì M T, D 'A mbrosi N. A LS: Focus on purinergic signalling. Pharmacology & Therapeutics. 2011 ; 132: 111-22
11. Hask ò G, Linden J, Cronstein B N, Pacher P. A denosine receptors: Therapeutic aspects for infl ammatory and immune diseases. Nat Rev Drug Discover. 2008 ; 7: 759-70
12. Gessi S, Merighi S, Varani K, Borea PA. A denosine receptors in health and disease. Adv Pharmacol. 2011 ; 61: 41-75
13. Ramekers B P, Riksen N P, van der Hoeven J G, Smits P, Pickkers P. Modulation of innate immunity by adenosine receptor stimulation. Shock. 2011; 36: 208-15
14. Varani K, Laghi-Pasini F, Camurri A, Capecchi PL, Maccherini M, Diciolla F, et al. Changes of peripheral A 2A adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J. 2003 ; 17: 280-2
15. Gessi S, Cattabriga E, Avitabile A, Gafa' R, Lanza G, Cavazzini L, et al. Elevated expression of A 3 adenosine receptors in human colorectal cancer is refl ected in peripheral blood cells. Clin Cancer Res. 2004 ; 10: 5895-901
16. Brooks BR, Miller RG, Swash M, Munsat T L. E l Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 ; 1: 293-9
17. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). Neurol Sci. 1999 ; 169: 13-21
18. Brinkmann JR, Andres P, Mendoza M, Sanjak M. G uidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci. 1997 ; 147: 97-111
19. Varani K, Massara A, Vincenzi F, Tosi A, Padovan M, Trotta F, et al. Normalization of A 2A and A 3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumour necrosis factor alpha but not methotrexate. Arthritis Rheum. 2009 ; 60: 2880-91
20. Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, et al. A 2A and A 3 adenosine receptor expression in rheumatoid arthritis: Up-regulation, inverse correlation with disease activity score and suppression of infl ammatory cytokine and metalloproteinase release. Arthritis Res Ther. 2011; 13: R197
21. Varani K, Vincenzi F, Tosi A, Targa M, Masieri F F, Ongaro A, et al. Expression and functional role of adenosine receptors in regulating infl ammatory responses in human synoviocytes. Br J Pharmacol. 2010 ; 160: 101-15
22. Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, et al. [3H]-MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol Pharmacol. 2000 ; 57: 968-75
23. Varani K, Gessi S, Merighi S, Vincenzi F, Cattabriga E, Benini A, et al. Pharmacological characterization of novel adenosine ligands in recombinant and native human A 2B receptors. Biochem Pharmacol. 2005 ; 70: 1601-12
24. Simola N, Morelli M, Pinna A. A denosine A 2A receptor antagonists and Parkinson's disease: State of the art and future directions. Curr Pharm Des. 2008 ; 14: 1475-89
25. Mizuno Y, Haegawa K, Kondo T, Kuno S, Yamamoto Y. Japanese Istradefylline Study Group. Clinical Efficacy of istradefylline (KW 6002) in Parkinson's disease: A randomized, controlled study. Mov Disord. 2010; 25: 1437-43
26. Ciccarelli R, Ballerini P, Sabatino G, Rathbone MP, D'Onofrio M, Caciagli F, et al. Involvement of astrocytes in purine-mediated separative processes in the brain. Int J Dev Neurosci. 2001 ; 19: 395-414
27. Halassa MM, Haydon PG. I ntegrated brain circuits: Astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol. 2010 ; 72: 335-55
28. Mojsilovic-Petrovic J, Jeong G B, Crocker A, Arneja A, David S, Russel DS, et al. Protecting motor neurons from toxic insult by antagonism of adenosine A 2A and Trk receptors. J Neurosci. 2006 ; 26: 9250-63
29. Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, et al. Adenosine A 2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and 'fine tuning' modulation. Prog Neurobiol. 2007 ; 83: 310-31
30. Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP. Functions, dysfunctions and possible therapeutic relevance of adenosine A 2A receptors in Huntington's disease. Prog Neurobiol. 2007 ; 81: 331-48
31. Komaki S, Ishikawa K, Arakawa Y. T rk and cAMP-dependent survival activity of adenosine (A 2A) agonist CGS21680 on rat motor neurons in culture. Neurosci Lett. 2012 ; 522: 21-4
32. Yanpallewar S U, Barrick C A, Buckley H, Becker J, Tessarollo L. Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2012; 7: E39946
33. Impellizzeri D, Di Paola R, Esposito E, Mazzon E, Paterniti I, Melani A, et al. CGS 21680, an agonist of the adenosine (A 2A) receptor, decreases acute lung infl ammation. Eur J Pharmacol. 2011; 668: 305-16
34. Garcia G E, Truong L D, Chen J F, Johnson R J, Feng L. Adenosine (A 2A) receptor activation prevents progressive kidney fi brosis in a model of immune-associated chronic infl ammation. Kidney Int. 2011 ; 80: 378-88
35. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al. Adenosine A 2A or A 3 receptors are required for inhibition of infl ammation by methotrexate and its analog MX-68. Arthritis Rheum. 2003 ; 48: 240-7